Lawrence Hineline - Intracellular Vice President and CFO
| ITCI Stock | USD 71.81 0.49 0.68% |
President
Mr. Lawrence J. Hineline CPA is the Chief Financial Officer, Senior Vice President Finance, Treasurer, Assistant Secretary of IntraCellular Therapies, Inc. Mr. Hineline has served as Senior Vice President of Finance of the Company since January 2019 and Chief Financial Officer and Treasurer of the Company since the Merger in August 2013. He also served as Vice President of Finance of the Company from the Merger in August 2013 to December 2018. He has served as Vice President of Finance, Chief Financial Officer and Secretary of ITI since June 2002. Mr. Hineline also served as the Secretary of the Company from August 2013 until September 2014. From December 2000 to November 2003, Mr. Hineline was the Vice President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporationrationrate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a startup and was later acquired by Baxter Health Care since 2019.
| Age | 61 |
| Tenure | 5 years |
| Professional Marks | CPA |
| Address | 430 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.1343) % which means that it has lost $0.1343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2239) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Steven Whaley | Walmart | 56 | |
| Robert Pate | Chevron Corp | 57 | |
| Marc Baer | Air Lease | 54 | |
| Ron Coughlin | HP Inc | 50 | |
| Pierre Breber | Chevron Corp | 60 | |
| Clay Neff | Chevron Corp | 62 | |
| M Nelson | Chevron Corp | 53 | |
| Jacqueline Canney | Walmart | 50 | |
| Anoop Kumar | Chevron Corp | N/A | |
| Joseph Geagea | Chevron Corp | 60 | |
| Suresh Kumar | Walmart | 58 | |
| David Chojnowski | Walmart | 50 | |
| James Bergkamp | HP Inc | N/A | |
| David Payne | Chevron Corp | N/A | |
| Alex Khatibi | Air Lease | 63 | |
| Lori Johnston | Amgen Inc | 53 | |
| Jie Chen | Air Lease | 57 | |
| Sean Harper | Amgen Inc | 54 | |
| John Poerschke | Air Lease | 62 | |
| James Johnson | Chevron Corp | 65 | |
| Todd Morgenfeld | HP Inc | 41 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Wennogle, Vice President of Drug Discovery | ||
| Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs | ||
| Michael Rawlins, Director | ||
| Robert Nostrand, Independent Director | ||
| Richard Lerner, Director | ||
| Allen Fienberg, Co-Founder and VP of Bus. Devel. | ||
| Suresh MD, Executive Officer | ||
| Willie MD, Senior Development | ||
| Lawrence CPA, CFO, Finance | ||
| Kimberly Vanover, VP of Clinical Devel. | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs | ||
| CPA CPA, CFO, Fin | ||
| Christopher Alafi, Director | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Michael Halstead, Sr. VP, General Counsel and Secretary | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Andrew Satlin, Executive Vice President and Chief Medical Officer | ||
| Michael JD, General VP | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| Rory Riggs, Independent Director | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Joel Marcus, Director | ||
| Lawrence Hineline, Vice President and CFO |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 6.52 B | ||||
| Shares Outstanding | 105.36 M | ||||
| Shares Owned By Insiders | 2.35 % | ||||
| Shares Owned By Institutions | 92.11 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (6.56) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.